Literature DB >> 31182257

Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now?

Ghadeer A R Y Suaifan1, Aya A M Mohammed2.   

Abstract

Fluoroquinolones are considered one of the widely utilized antibiotics, specifically, with the recent development of newer generations such as moxifloxacin, delafloxacin and finafloxacin which possess a wider spectrum of activity and improved bioavailability. However, alarming increase in bacterial resistance reports worldwide incites medicinal chemists to employ guided-biologically-oriented-synthesis-strategies toward the modulation of quinolones derivatives activity. At present, quinolone scaffold diverse biological activities prompted the fortuitous discovery of novel antimicrobial and anticancer derivatives. Herein, the opponent arguments (2013-2015) regarding the structure activity relationships of fluoroquinolones' antibacterial, anticancer, antifungal activities are inscribed.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer; Antimycobacterial; Bacterial resistance; Ciprofloxacin; Fluoroquinolones; Hybrid

Mesh:

Substances:

Year:  2019        PMID: 31182257     DOI: 10.1016/j.bmc.2019.05.038

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Interaction between moxifloxacin and Mcl-1 and MITF proteins: the effect on growth inhibition and apoptosis in MDA-MB-231 human triple-negative breast cancer cells.

Authors:  Artur Beberok; Jakub Rok; Zuzanna Rzepka; Krzysztof Marciniec; Stanisław Boryczka; Dorota Wrześniok
Journal:  Pharmacol Rep       Date:  2022-09-01       Impact factor: 3.919

Review 2.  Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.

Authors:  Xi Wang; Yuanxun Wang; Xuemin Li; Zhenyang Yu; Chun Song; Yunfei Du
Journal:  RSC Med Chem       Date:  2021-08-10

3.  The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux.

Authors:  Julia Vergalli; Alessio Atzori; Jean-Marie Pagès; Jelena Pajovic; Estelle Dumont; Giuliano Malloci; Muriel Masi; Attilio Vittorio Vargiu; Mathias Winterhalter; Matthieu Réfrégiers; Paolo Ruggerone
Journal:  Commun Biol       Date:  2020-04-28

4.  Design, Synthesis and Biological Evaluation of New Piperazin-4-yl-(acetyl-thiazolidine-2,4-dione) Norfloxacin Analogues as Antimicrobial Agents.

Authors:  Gabriel Marc; Cătălin Araniciu; Smaranda Dafina Oniga; Laurian Vlase; Adrian Pîrnău; George Cosmin Nadăș; Cristiana Ștefania Novac; Ioana Adriana Matei; Mariana Carmen Chifiriuc; Luminița Măruțescu; Ovidiu Oniga
Journal:  Molecules       Date:  2019-10-31       Impact factor: 4.411

5.  Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.

Authors:  Krzysztof Marciniec; Artur Beberok; Paweł Pęcak; Stanisław Boryczka; Dorota Wrześniok
Journal:  Pharmacol Rep       Date:  2020-10-15       Impact factor: 3.024

6.  UVA Radiation Enhances Lomefloxacin-Mediated Cytotoxic, Growth-Inhibitory and Pro-Apoptotic Effect in Human Melanoma Cells through Excessive Reactive Oxygen Species Generation.

Authors:  Artur Beberok; Zuzanna Rzepka; Jakub Rok; Klaudia Banach; Dorota Wrześniok
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

Review 7.  Fluoroquinolones' Biological Activities against Laboratory Microbes and Cancer Cell Lines.

Authors:  Ghadeer A R Y Suaifan; Aya A M Mohammed; Bayan A Alkhawaja
Journal:  Molecules       Date:  2022-03-03       Impact factor: 4.411

Review 8.  The New Face of a Well-Known Antibiotic: A Review of the Anticancer Activity of Enoxacin and Its Derivatives.

Authors:  Karolina Jałbrzykowska; Alicja Chrzanowska; Piotr Roszkowski; Marta Struga
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

Review 9.  State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections.

Authors:  Amanda Cano; Miren Ettcheto; Marta Espina; Ana López-Machado; Yolanda Cajal; Francesc Rabanal; Elena Sánchez-López; Antonio Camins; Maria Luisa García; Eliana B Souto
Journal:  J Nanobiotechnology       Date:  2020-10-31       Impact factor: 10.435

10.  Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.

Authors:  Tommaso Felicetti; Violetta Cecchetti; Giuseppe Manfroni
Journal:  J Med Chem       Date:  2020-07-30       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.